CORVUS PHARMACEUTICALS, INC. - JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CORVUS PHARMACEUTICALS INC
Welcome to the Jefferies 2026 Health Care Conference. Please welcome Jeff Arcara, Chief Business Officer at Corvus. Thank you. Thank you, my name is Jeff Arcera. I'm the Chief Business officer for Corvuss Pharmaceuticals. This afternoon we'll spend a few minutes providing an overview of Corviss as well as our pipeline, and we'll focus specifically on Socolitinib, which is our novel oral highly selective ITK inhibitor. We'll also review some of our clinical data as well as some of the key clinical data readouts that we'll see starting in Q1 2027 and throughout the entire year. This is our forward-looking statement. You can review this statement along with our slides on our investor website. So first, who is Corvus? We're a clinical stage company developing novel immune modulators for the treatment of cancer and immune diseases. We have our lead program, Socolitinib, which is in a phase three registrational trial for peripheral T-cell lymphoma, which is a really tough cancer to treat, as well as a phase two program in moderate to severe atopic dermatitis. That's called the Sierra One trial, and both those trials are enrolling. Socolinib represents a pipeline and a product opportunity for us. So we have a number of additional clinical trials that we're running, including HS, which just started enrolling last month, as well as we are going to start an asthma study in the beginning of 2027. ITK is a platform technology for us. We have a member of Next Generation and Backup Compounds and Development. And we have strong IP protection through November of 2037, and that's 2042 if you include pharmaceutical extensions. And finally, on the bottom of the slide, you can see we have Chinese partner, Angel Pharmaceuticals, who we own 49% of, and they are running clinical trials with socalitinib in China as well, including an AD study, which we will talk about in a few slides. So first, why ITK? ITK stands for interleukin-2 inducible T-cell kinase. It's involved in T-cel receptor signaling and differentiation. If you look at the left-hand side of the slide, you can see naive CD4 T-cells can differentiate into Th1, Th2, or Th17 cells. If you look at the right-hand side of the slide, essentially how socalitinib works is we block Th2 and Th17 and their respective cytokines. So think IL-4, 5, and 13 like dupixent. Think IL-17 like abimxelix. And what that does is that skews the immune response towards the Th1 cells, which are involved in fighting cancer and viral elimination. It's also important to note, if you look at the upper right-hand side of the slide, we're very selective for ITK, but we spare RLK. RLk stands for resting lymphocyte kinase. It is a redundant T-cell signaling pathway, and by sparing that, we help preserve the Th1 response. If you look to the lower right- hand of the slide, in addition to us blocking TH17 and IL-17, we've shown that we can shift or switch TH17 cells to become active Treg cells. So in essence, we're taking the foot off the gas by lowering the cytokines, and we're putting the foot on the brake at the same time by increasing Tregs. So we're modulating or rebalancing the immune system. We're not suppressing it. So how do we accomplish that? We accomplish that through some really smart science and making a very targeted and selective drug. As you can see in the center of that slide, you can see the kinome tree showing specific for ITK. If you look at the upper left-hand corner of that side, that's a specific binding table. KD, the lower the KD the more strong the binding. The first row ITK 6.5, very strong binding for ITK. If you look at the very bottom, RLK 2700. So we're highly selective for ITk over RLk as well as other tech family kinases. That's important not only for efficacy, but also for safety. So why do I say that? ITK has very limited tissue distribution. It is primarily on NK cells and T cells. And as you can see, we're very selective just for ITK. So with that, we expect limited off-target effects because of that, and that's actually played out in our clinical data. We've seen a very good safety profile comparable to placebo. So how does this compare to currently approved therapeutic agents? Because we work more upstream, blocking Th2 and Th17, You can see in that first row, the green across, we block a broader set of cytokines. This does two things for us. It allows us to treat a broader Set of Patients. So, for example, patients that may have failed prior therapies or patients that have a disease that involves both Th2 and Th17. So think atopic dermatitis, think asthma. It also allows us To treat a Broader Set of Diseases. So in addition to Th2 and Th17-driven diseases, we believe we can treat IL-5-driven diseases as well as fibrotic diseases. And we actually have preclinical data models in atopic dermatitis, asthma, psoriasis, systemic sclerosis, IPF, and colitis models, and others. So there's a lot more we can do with socalitinib, but also with our next-generation ITK inhibitors. When you look at all these diseases together, They make up a very significant targeted addressable market. 130 million patients across the G7. About 20 million of those would be our more severe, moderate-to-risk patients that we would treat. On the right-hand side, you can see that market is projected to be $170 billion, with just a fraction of that being orals, only 10%. So a significant opportunity for a novel, safe oral therapy in INI diseases. so let's take a closer look at our pipeline and what's the clinical data that's going to drive our readouts in 2027 so at the top of the slide i mentioned we have a trial in a phase three trial in peripheral t-cell lymphoma that's actually in relapsed and refractory ptcl that is a really tough disease to treat a current standard of care is inadequate it's not tolerated very well it doesn't work very well. NCCN guidelines actually recommend a clinical trial in place of those drugs currently. So significant unmet need for us to fill. You can see in that center column, we have a futility analysis that will be happening in Q1, 2027. We also have orphan drug designation and fast track designation. In terms of phase two trials, we have the atopic dermatitis trial. That's the CR1 trial. That will read out in Q3 of 2027, and then we also will be starting an asthma trial. That will start in Q1. Because of the mechanism of action that we just talked about, we are going to actually enroll both T2 and non-T2 asthma patients because we can block both TH2 and TH17. What we will do is that we will have an interim analysis and we'll look at each of those groups separately. And if we see a non-performing group, we will drop them from the trial so we can continue the trial to keep going. In the middle, in terms of phase one, in the middle you can see We have an HS study that just started. That is a TH17-driven disease, right? You look at Bimxelix, which blocks IL-17A and F. This is the first time we're going into a TH 17 disease in HS, so we designed this as a true proof-of-concept study, but it will read out relatively quickly in the first half of 2027. And at the bottom, ANGEL, our partner in China, will look more into the study. They have their first cohort done and enrolled, and that data will readout in March of 20 27. The second cohort will start enrolling now in November, and that data should be available in the second half of 2027. So speaking of AD, let's look at the clinical data a little closer. So this is our Phase I trial design. Just to base that, everyone, there was a total of 72 patients with moderate to severe atopic dermatitis, 48 on drug, 24 on placebo. We did four cohorts. Cohorts 1 and 2 are the low-dose cohorts. They were randomized 3 to 1, so 12 on drug, 4 on placebo. These were four weeks of treatment, and it was a QD versus BID. Cohorts 3 and 4 are our higher dose. That's four weeks, and then we have the low dose cohorts, four weeks for treatment and eight weeks of treatement, respectively, for, again, a total of 72 patients. If you look at the study design on the right, it's pretty standard. It's safety is the primary endpoint, but we also looked at change in EASY score, EASI 75, 99, J01. one. It's also important to note there were no concomitant steroids. So this is monotherapy data that we're showing. So what did the trial show? We saw that with increasing the dose and increasing the duration, we saw deeper responses and more durable responses. So on the left-hand side is our first three cohorts. That was, again, four weeks of data. Really, the focus is on the right-hand side. That's our cohort four data. Again, that was eight weeks of treatment. It's the higher dose. If you look at that blue bar, that's EZ75. We saw a 75% response rate versus placebo at 20. So that's actually comparable to a JAK level of efficacy. If you Look at the right-hand side, the light blue bar at 33%, that's IgA01. That's actually Comparable to a biologic level. So right now, we're sitting somewhere between a biologics and a JAC in terms of level of efficacy. And again, that is for cohort four. If you look at all of the patients together, on the left-hand side, you can see the orange line is the placebo cohorts one through four. The blue line isthe active group, socolitinib. What you cansee is a significant separation from placebo starting as early as two weeks. On the right-handside, as a reminder, we had 35% of our patients having a prior systemic therapy. So that's what you're seeing on the right side. It works. Socolitib worked just as well, but what happened is you canseeplacebo does not work as well. what you would expect in terms of treating sicker patients. Both of those are statistically significant separations from placebo. We also looked at true treatment-resistant patients. So we did case studies. We found six patients in total in cohorts three and four that actually were resistant to drugs like Dupixent or Rinvox, even OX40 that is no longer with us. The four patients with socalitinib, three of the four responded to therapy, as you can see on the right-hand side, and the two placebos actually flared. In addition to looking at response, we also looked at durability of treatment. So what you can See on the left-hand side is the first three cohorts, EZ75, just under 40%. In the gray box, that's off of treatment, so 90 days off of treatment, we saw that the response was still at the same level. And on the right-hand side is cohort four. Again, that was a 75% response. In the gray box, you can see 30 days off of therapy. They maintain their level of response. So this is interesting for us to look at and think about. This is where the Treg story starts to come into play if we can create more of a durable response by increasing Tregs. And we're going to look a little bit more at that. We're going look at this more deeply in our phase two CR1 trial. We have a 90-day follow-up period. So we're not the only ones that looked at this. The JAKs and the biologists looked at this as well, and you can see on this slide essentially after stopping treatment with JAK or a biologic, patients rebounded as quickly as one week. So in addition to the clinical data, we also looked at biomarker data and see a consistent effect on Th2 immunology. On the left hand side, you can a dose response reduction in Th2 cells. In the center panel and right panel our cohorts three and four, we saw a reduction now four, five, 13 in TARC, and it's both on therapy and in the gray box off there we saw reduction. As I mentioned Tregs, we actually looked at Treg and saw we had persistent increase in Treg in both on treatment and off treatment. If you look at the upper row, that's 20 days on treatment, 28 days on treatement, cohorts 3, cohords 4, and combined. The bottom row is 30 days off of treatment. If you look at the lower right-hand box there, you can see we actually had a significant separation from placebo in terms of increased Tregs out to 30 days. And as important as efficacy is, safety is probably even more important in terms atopic dermatitis. You're treating 18-year-olds with eczema. Overall, we have a very good safety profile with socalitinib to date. You can see pretty much comparable to placebo, even if you look at grade 3 serious AEs or any AEs leading to discontinuation of the drug. So in summary, for the AD data, we saw positive clinical results. We saw EZ75 in terms of response rates. We also saw a very favorable safety profile. We saw deeper and durable responses, including no rebound. we've seen response in challenging patients like those that have failed therapies and we've seeing supportive biomarker data that supports immune rebalancing so in the last few minutes let's just review some of the current studies we have underway so this is our phase two trial called sierra one it's 12 weeks of treatment with 90 day follow-up you can see on the left hand side it's moderate severe greater 18 years of age moderate to severe AD greater than 18 years of age easy score of greater than 16 Travel's hard I just lost my voice There's two slides left Let's see if I can get through it I can't. You want to just clear these last two slides? Sure. I'm there. I apologize. No problem. Hey, everyone. Zach Kubo, Investor Relations. So this slide shows the Sierra 1 Phase 280 trial that's enrolling now. You can see that we're looking at four cohorts of 50 patients each, 200 milligrams QD, 200 milligrams BID, and 400 milligrams QT versus placebo. And we are planning to announce results for this in Q3 of 2027. So our partner in China, Angel Pharma, is also running a clinical trial in atopic dermatitis. And that's a Phase 1B, Phase 2 trial. The first Phase 1D portion is enrolling now. Cohort 1 has completed enrollment. We expect to announce data from that in March of 2027. We've announced that the baseline characteristics from that patient group of 24 patients is similar to the baseline characteristic of our own Phase I trial that we just showed data from. And we anticipate that they'll start enrolling Cohort 2 of that trial in late November of this year, with that data coming in the second half of 2026. And then after the Phase 1B portion, they can choose to extend the trial into 60 to 90 additional patients at a dose that they select based on the results of the Phase 2B. So in the end of September, we announced the initiation of a Hidranitis Superativa Phase 1b trial. This is a proof-of-concept trial in HS, which is a Th17 disease, so it's the first time we're going to be looking at a TH17-specific disease. And it's a 12-week trial enrolling up to 25 patients. It's open-label, no placebo. And we're looking at safety and then efficacy endpoints, HIS-COR and ISH4 at 12 weeks. And we'll also be looking AT skin and blood biomarkers to measure that impact on IL-17. So in conclusion here this is our exciting 2027 milestone value driving milestone path. We'll start with the asthma initiation trial. The initiation of an asthma trial in early Q1. We will have a PTCL futility analysis for the phase three trial in Q1 in March 2027. We have the phase 1b cohort one top line and then in the second quarter our partner angel will be initiating their own asthma trial the HS data we expect to have in the first half of 2027 and after that we expect have the Sierra one phase two atopic dermatitis trial data in q3 2027 the angel cohort two data will come in the second half of the year and then the PTCL phase three top line data by year and 2027 so an exciting year that we're looking forward to reporting out and with that that's our last slide have time. The best we can. So how big is the PTCL market? It's about 70,000 prevalence globally, 10,000 in the US, 15,000 in Europe and about 30,000 rest of world. US market incidence is about 3,300 patients. No questions? Thank you for your time.
- Company
- CORVUS PHARMACEUTICALS INC
- Keywords
- CORVUS PHARMACEUTICALS INC